Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and Colombia.
- Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royalties on future sales of the product
- Agreement covers commercialization of BIO101 in Latin America
- Biophytis and Blanver intend to collaborate on manufacturing and joint clinical development for Latin America